EXPEDITING THE PATH
TO PATIENTS

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to cirrhosis, liver failure, and the need for transplantation. Current approved treatments benefit only a small percentage of patients, and many late-stage therapies have shown only modest improvements.

TGM-312 is being developed to target steatosis, inflammation, and fibrosis, with the potential for patient-friendly quarterly dosing. In preclinical studies using a highly translatable model of MASH, TGM-312 significantly reduced liver fat accumulation, inflammation, and markers of fibrosis. TGM-312 showed strong monotherapy activity and synergistic effects in combination with approved and emerging therapies, supporting its potential to treat disease across multiple stages and bring benefit to a broad range of patients.

Bleeding disorders affect around 8 million people worldwide, causing uncontrolled bleeding episodes, joint damage, and reduced quality of life. While treatments for hemophilia have advanced, people with other bleeding disorders, such as von Willebrand Disease, still face limited options, high treatment burden, and inconsistent care.

TGM-148 is being developed as a universal hemostatic agent that can provide safe, low-burden protection across multiple bleeding disorders. In preclinical models of four different bleeding disorders, TGM-148 significantly improved clotting parameters and reduced bleeding events. Importantly, these benefits were achieved without signs of increased thrombosis risk. With a convenient subcutaneous regimen of just four doses a year, TGM-148 has the potential to offer a safe and effective treatment across bleeding disorders.

TGM-148 is on track for a regulatory submission and clinical entry during 2026.